Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Aims to Top SGLT-2 Inhibitor Market with Apleway
April 18, 2014
- “MRs’ Manners” Are Opening Theme in Panel Discussion Held by MREAC
April 18, 2014
- Sales of Diovan Fell 22% in 3rd Quarter of FY2013; Overall Growth of ARB Market Could Fall Short of Expectations
April 18, 2014
- Boehringer Ingelheim Reports 14.1% Increase in Operating Profit to 2,114 Million Euro in 2013
April 17, 2014
- Metal Found in Voltaren Product Again: Novartis
April 17, 2014
- AZ Offers Sales Rep Jobs to over 100 New Graduates in FY2014
April 16, 2014
- Eisai President Naito Awarded Honorary KBE
April 16, 2014
- FY2015 Recruitment Plan: Eisai to Resume Offering Jobs to New Graduates
April 15, 2014
- Novartis Pharma Notified Police about Metal Object Found in Voltaren Product
April 15, 2014
- Hisamitsu Total Sales Up 5.5% but Domestic Ethical Drug Sales Down 1.8%
April 14, 2014
- Patient Enrollment for PI Trial of Anticancer Drug HF10 in US Completed, Takara Bio
April 14, 2014
- RaQualia, Asahi Kasei Pharma Conclude Joint Drug Discovery Research
April 14, 2014
- 10% of Valsartan Franchise Prescriptions Switched to Other ARBs, Azilva, Micamlo Top Lists
April 11, 2014
- Chugai Files NDA for Vemurafenib for Melanoma with BRAF Mutation, Roche Diagnostics Files for Companion Diagnostics
April 11, 2014
- 17 Patients Who Took Xeplion Have Died since November Launch
April 10, 2014
- Kyowa Kirin Completes Biopharmaceutical API Manufacturing Facility, Eying Start of Operations from 2016
April 10, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
April 9, 2014
- US Jury Orders Takeda to Pay US$6 Billion in Punitive Damages
April 9, 2014
- GSK Voluntarily Recalls Paxil in Japan, No Reports of Adverse Reactions
April 9, 2014
- ViiV, Shionogi to Copromote Anti-HIV Drug Tivicay at 100 Major Facilities
April 9, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…